Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSC and SVF Injection for Knee Osteoarthritis
NCT03164083Phase 2Withdrawn
- Sponsor
- SCARM Institute
- Start
- Nov 2019
- Primary completion
- Aug 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, triple-blind trial of mesenchymal stem cells and autologous adipose stromal vascular fraction in osteoarthritis (OA) (2 arms), sponsored by SCARM Institute. Primary endpoints: physical function improvement at 2 weeks and Change in pain density at 2 weeks. Planned start Nov 2019; status: withdrawn.
02
Drugs
mesenchymal stem cellsautologous adipose stromal vascular fraction
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT03164083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03164083.